Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41

PLoS Pathogens

Volumn 6, Issue 11, 2010, Pages

  Sabin, Charles ^a   Corti, Davide ^b,d   Buzon, Victor ^a   Seaman, Mike S ^c   Hulsik, David Lutje ^a   Hinz, Andreas ^a   Vanzetta, Fabrizia ^d   Agatic, Gloria ^d   Silacci, Chiara ^b   Mainetti, Lara ^e   Scarlatti, Gabriella ^e   Sallusto, Federica ^b   Weiss, Robin ^f   Lanzavecchia, Antonio ^b,g   Weissenhorn, Winfried ^a  

^a UNIV GRENOBLE ALPES   (France)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Humabs SAGL ^*  (Switzerland)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 41; HK20 ANTIBODY; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; HEAVY CHAIN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; VIRUS NEUTRALIZATION; CHEMISTRY; CRYSTALLIZATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; PROTEIN CONFORMATION; SERODIAGNOSIS; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; MUTATION; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; SURFACE PLASMON RESONANCE;

EID: 79251506314     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1001195     Document Type: Article

References (65)

1. Walker LM, Burton DR (2010) Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Current Opinion in Immunology 22(3): 358-66.
2. Buonaguro L, Tornesello ML, Buonaguro FM (2007) Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 81: 10209-10219.
3. Karlsson Hedestam GB, Fouchier RAM, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. 6: 143-155.
4. Walker LM, Burton DR (2010) Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22: 358-366.
5. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, et al. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763-767.
6. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, et al. (1984) Lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312: 767-768.
7. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-1028.
8. Moore JP, Trkola A, Dragic T (1997) Co-receptors for HIV-1 entry. Curr Opin Immunol 9: 551-562.
9. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700.
10. Weissenhorn W, Hinz A, Gaudin Y (2007) Virus membrane fusion. FEBS Lett 581: 2150-2155.
11. Harrison SC (2008) Viral membrane fusion. Nat Struct Mol Biol 15: 690-698.
12. Munoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R (1998) Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol 140: 315-323.
13. Furuta RA, Wild CT, Weng Y, Weiss CD (1998) Capture of an early fusionactive conformation of HIV-1 gp41. Nat Struct Biol 5: 276-279.
14. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, et al. (2004) Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3: 215-225.
15. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
16. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
17. Caffrey M, Cai M, Kaufman J, Stahl SJ, Wingfield PT, et al. (1998) Threedimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J 17: 4572-4584.
18. Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, et al. (2010) Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External Regions. PLoS Pathog 6: e1000880.
19. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, et al. (2000) Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151: 413-423.
20. de Rosny E, Vassell R, Jiang S, Kunert R, Weiss CD (2004) Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol 78: 2627-2631.
21. Dimitrov AS, Jacobs A, Finnegan CM, Stiegler G, Katinger H, et al. (2007) Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry 46: 1398-1401.
22. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, et al. (2008) A fusionintermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A 105: 3739-3744.
23. Miller MD, Geleziunas R, Bianchi E, Lennard S, Hrin R, et al. (2005) A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 102: 14759-14764.
24. Nelson JD, Kinkead H, Brunel FM, Leaman D, Jensen R, et al. (2008) Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377: 170-183.
25. Louis JM, Nesheiwat I, Chang L, Clore GM, Bewley CA (2003) Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 278: 20278-20285.
26. Louis JM, Bewley CA, Gustchina E, Aniana A, Clore GM (2005) Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41. J Mol Biol 353: 945-951.
27. Gustchina E, Louis JM, Lam SN, Bewley CA, Clore GM (2007) A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol 81: 12946-12953.
28. Gustchina E, Louis JM, Frisch C, Ylera F, Lechner A, et al. (2009) Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naive human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth. Virology 393: 112-119.
29. Bianchi E, Joyce JG, Miller MD, Finnefrock AC, Liang X, et al. (2010) Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediateyields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A 107(23): 10655-10660.
30. Root MJ, Kay MS, Kim PS (2001) Protein design of an HIV-1 entry inhibitor. Science 291: 884-888.
31. Luftig MA, Mattu M, Di Giovine P, Geleziunas R, Hrin R, et al. (2006) Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol 13: 740-747.
32. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS (1999) Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99: 103-115.
33. Sia SK, Carr PA, Cochran AG, Malashkevich VN, Kim PS (2002) Short constrained peptides that inhibit HIV-1 entry. Proc Natl Acad Sci U S A 99: 14664-14669.
34. Corti D, Langedijk JPM, Hinz A, Seaman MS, Vanzetta F, et al. (2010) Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals. PLoS ONE 5(1): e8805.
35. Schibli DJ, Weissenhorn W (2006) Class I and class II viral fusion protein structures reveal similar principles in membrane fusion. Mol Membr Biol 21: 361-371.
36. Hamburger AE, Kim S, Welch BD, Kay MS (2005) Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 280: 12567-12572.
37. Stoddart CA, Nault G, Galkina SA, Thibaudeau K, Bakis P, et al. (2008) Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J Biol Chem 283: 34045-34052.
38. Suhre K, Sanejouand Y-H (2004) ElNemo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement. Nucl Acids Res 32: W610-614.
39. Montgomery DL, Wang YJ, Hrin R, Luftig M, Su B, et al. (2009) Affinity maturation and characterization of a human monoclonal anti2body against HIV-1 gp41. MAbs 1: 462-474.
40. Gagnon P, Hensel F, Richiersi R (2008) Purification of IgM monoclonal antibodies. BioPharm International Supplements Mar 2 2008.
41. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 89: 10537-10541.
42. Ferrer M, Kapoor TM, Strassmaier T, Weissenhorn W, Skehel JJ, et al. (1999) Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 6: 953-960.
43. Vincent N, Kone A, Chanut B, Lucht F, Genin C, et al. (2008) Antibodies purified from sera of HIV-1-infected patients by affinity on the heptad repeat region 1/heptad repeat region 2 complex of gp41 neutralize HIV-1 primary isolates. Aids 22: 2075-2085.
44. Fenyo EM, Heath A, Dispinseri S, Holmes H, Lusso P, et al. (2009) International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4: e4505.
45. Choudhry V, Zhang MY, Harris I, Sidorov IA, Vu B, Dimitrov AS, et al. (2006) Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun 348: 1107-1115.
46. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB (2009) HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137: 433-444.
47. Rimsky LT, Shugars DC, Matthews TJ (1998) Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 72: 986-993.
48. Lu J, Deeks SG, Hoh R, Beatty G, Kuritzkes BA, et al. (2006) Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 43: 60-64.
49. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, et al. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4: 1302-1307.
50. Naider F, Anglister J (2009) Peptides in the treatment of AIDS. Curr Opin Struct Biol 19: 473-482.
51. Hrin R, Montgomery DL, Wang F, Condra JH, An Z, et al. (2008) Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. AIDS Res Hum Retroviruses 24: 1537-1544.
52. Stewart KD, Steffy K, Harris K, Harlan JE, Stoll VS, et al. (2007) Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery. J Comput Aided Mol Des 21: 121-130.
53. Eckert DM, Malashkevich VN, Kim PS (1998) Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. J Mol Biol 284: 859-865.
54. Leslie AGW (1992) Recent changes to the MOSFLM package for processing film and image plate data. Jnt CCP4/ESF-EACMB Newslett Protein Crystallogr 26.
55. Evans P (2006) Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62: 72-82.
56. CCP4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 157-163.
57. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
58. Perrakis A, Morris R, Lamzin VS (1999) Automated protein model building combined with iterative structure refinement. Nat Struct Biol 6: 458-463.
59. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
60. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255
61. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
62. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, et al. (2006) Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80: 11776-11790.
63. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, et al. (1997) In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokinemediated suppression. Nat Med 3: 1259-1265.
64. Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, et al. (2002) Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol 76: 9035-9045.
65. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, et al. (1993) Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis 168: 207-210.